相关临床试验
175
27 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1957
进行中（未招募）
13
7.4%
已完成
78
44.6%
尚未招募
14
8.0%
招募中
41
23.4%
终止
8
4.6%
Unknown
20
11.4%
撤回
1
0.6%
暂无批准数据
- A Lancet study of nearly one million adults across seven high-income countries found that blood pressure and cholesterol levels in older adults with obesity now resemble those of normal-weight individuals, largely due to increased medication use. - The study analyzed 110 health datasets spanning 1990 to 2024, showing that pharmacological advances have successfully narrowed the metabolic risk gap in people over 40. - Researchers caution that obesity remains a major clinical problem, as the study did not assess diabetes, inflammation, insulin resistance, or cancer risk, all of which are linked to excess weight. - In younger people with obesity, metabolic risk remains significantly higher than in those of normal weight, and BMI-based definitions may obscure true cardiometabolic risk, particularly in Asian populations.
- Rejuvenate Biomed has completed patient recruitment for the MINT-COPD Phase 2 trial of RJx-01, targeting muscle wasting in COPD patients with topline data expected by end of 2026. - RJx-01 represents a first-in-class multi-target approach addressing mitochondrial dysfunction, inflammation, fibrosis, and neuromuscular impairment in sarcopenia treatment. - The trial addresses a significant unmet medical need, as sarcopenia affects 14-67% of COPD patients and over 50 million people globally with no approved drug treatments. - Previous Phase 1b data showed meaningful improvements in muscle strength, physical function, and fatigue resistance with excellent safety profile in healthy older men.
- A £1.2 million British Heart Foundation-funded trial is evaluating metformin's potential to halt abdominal aortic aneurysm growth, representing the largest drug trial ever conducted for this condition. - The international study aims to recruit 1,000 patients across the UK, Australia, and New Zealand, with participants receiving daily metformin or placebo until surgical intervention becomes necessary. - Laboratory research suggests metformin may prevent aneurysm enlargement by blocking aortic inflammation, offering hope for patients who currently have no treatment options for small aneurysms. - Success could provide a breakthrough treatment for a condition that causes approximately 4,000 deaths annually in the UK, potentially allowing patients to avoid high-risk surgical procedures.
- Zigakibart, an investigational anti-APRIL monoclonal antibody, demonstrated sustained efficacy with 60% proteinuria reduction from baseline at 100 weeks in IgA nephropathy patients. - Over half of patients (55%) achieved proteinuria below 500 mg/24h, with 31% reaching deeper remission below 300 mg/24h, while kidney function remained stable across all patient subgroups. - The treatment showed a reassuring safety profile with mostly mild to moderate adverse events and no treatment-related serious infections or discontinuations throughout the study period. - These represent the longest duration of kidney function stabilization reported for an anti-APRIL agent in IgA nephropathy, supporting zigakibart's potential as a disease-modifying therapy.
- Rejuvenate Biomed has dosed the first subject in a randomized Phase II trial evaluating RJx-01 for muscle weakness and sarcopenia in COPD patients, addressing a condition with no currently approved treatments. - The double-blind, placebo-controlled study will enroll 130 older adults hospitalized with severe acute COPD exacerbation, measuring the drug's impact on muscle strength, physical function, and fatiguability. - RJx-01 previously demonstrated improvements in muscle strength and function in Phase I trials, targeting multiple cellular pathways related to muscle quality decline including mitochondrial health.
• UK researchers have demonstrated for the first time that PARP inhibitor niraparib can slow the progression of mesothelioma, reducing the risk of disease progression or death by 27% in patients who exhausted traditional treatments. • The NERO trial, conducted across 11 UK hospitals with 88 patients, showed the drug delayed cancer worsening by an average of 1.5 months compared to standard care, with some patients experiencing significantly longer disease control. • This breakthrough offers new hope for mesothelioma patients, an aggressive asbestos-linked cancer with only 5% five-year survival rate, and opens pathways for further research into tailored PARP inhibitor treatments.
- University of Leicester researchers conducted the first genome-wide study revealing genetic variations affect varenicline's effectiveness in smoking cessation, offering new insights into personalized treatment approaches. - The comprehensive analysis utilizing UK Biobank and international health records identified specific DNA variants linked to successful smoking cessation with varenicline treatment. - The groundbreaking findings illuminate the biological mechanisms underlying varenicline-aided smoking cessation, though researchers emphasize the need for larger confirmatory studies.
• Rejuvenate Biomed, University of Leicester, NIHR Leicester BRC, and Wellcome Leap have partnered to conduct a Phase 2 clinical trial evaluating RJx-01 for COPD-related sarcopenia, with patient enrollment expected to begin in the first half of 2025. • The double-blind placebo-controlled trial will assess RJx-01's safety and efficacy in 130 older individuals hospitalized with severe acute COPD exacerbations, focusing on maintaining muscle integrity and improving physical function. • RJx-01 previously demonstrated promising results in a Phase 1b trial, showing meaningful improvements in muscle strength, function, and fatigue resistance in people with disuse-induced muscle weakness.
